This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Duke University. Active years: 2017-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2019
Title: Innovations in Cancer Research by Sharareh Reihani
Introduction
Sharareh Reihani is a prominent inventor based in Chapel Hill, NC, specializing in cancer research. She has made significant contributions to the field with her innovative patents, focusing on biomarkers that aid in the diagnosis and treatment of various types of cancer. With a total of two patents to her name, her work is paving the way for advancements in cancer therapies.
Latest Patents
Reihani's latest patents include groundbreaking research on biomarkers for locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC). These patents provide methods and kits for predicting treatment response, determining likely survival rates, and assessing the aggressiveness of these conditions in patients. Additionally, she has developed biomarkers for high-grade serous ovarian carcinomas, which are instrumental in determining the prognosis of ovarian cancer. Her work offers compositions and methods that enable rationally directed therapies to improve outcomes for women suffering from high-grade serous carcinomas.
Career Highlights
Sharareh Reihani is affiliated with Duke University, where she continues her research and innovation in cancer biomarkers. Her dedication to improving cancer treatment through scientific research has established her as a key figure in her field.
Collaborations
Reihani collaborates with esteemed colleagues, including Mark W Dewhirst and Kouros Owzar, to further enhance her research efforts and contribute to the scientific community.
Conclusion
Sharareh Reihani's work in cancer research exemplifies the impact of innovative thinking in medicine. Her patents not only advance the understanding of cancer but also provide hope for improved treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
